| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CKLFSF8 |
| Uniprot No | Q8IZV2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-173aa |
| 氨基酸序列 | MEEPQRARSHTVTTTASSFAENFSTSSSSFAYDREFLRTLPGFLIVAEIVLGLLVWTLIAGTEYFRVPAFGWVMFVAVFYWVLTVFFLIIYITMTYTRIPQVPWTTVGLCFNGSAFVLYLSAAVVDASSVSPERDSHNFNSWAASSFFAFLVTICYAGNTYFSFIAWRSRTIQ |
| 预测分子量 | 19,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CKLFSF8重组蛋白的模拟参考文献示例(注：以下内容为基于领域知识的合理推测，非真实存在的文献)：
---
1. **文献名称**: *Expression and functional characterization of recombinant human CKLFSF8 in immune regulation*
**作者**: Li, X. et al.
**摘要**: 该研究通过原核表达系统成功制备了重组人CKLFSF8蛋白，并验证其体外趋化活性。实验表明，CKLFSF8可特异性招募单核细胞和T淋巴细胞，提示其在炎症反应中可能通过调控免疫细胞迁移发挥作用。
2. **文献名称**: *CKLFSF8 recombinant protein inhibits tumor angiogenesis via blocking VEGF signaling pathway*
**作者**: Wang, Y. et al.
**摘要**: 研究利用哺乳动物细胞表达体系获得高纯度CKLFSF8重组蛋白，并在小鼠模型中证实其通过抑制VEGF介导的内皮细胞增殖和血管生成，显著减缓实体瘤生长，为肿瘤靶向治疗提供新思路。
3. **文献名称**: *Structural insights into CKLFSF8-receptor interaction by cryo-EM*
**作者**: Zhang, R. et al.
**摘要**: 通过冷冻电镜技术解析了CKLFSF8重组蛋白与其受体CCR10的复合物三维结构，揭示了其独特的结合界面及信号转导机制，为设计靶向该通路的药物奠定结构基础。
4. **文献名称**: *CKLFSF8 in autoimmune diseases: Therapeutic potential of recombinant protein delivery*
**作者**: Chen, L. et al.
**摘要**: 研究评估了重组CKLFSF8蛋白在多发性硬化症模型中的治疗效果，发现其可通过调节Th17/Treg细胞平衡减轻自身免疫损伤，提示其在自身免疫疾病中的临床应用潜力。
---
注：以上内容为模拟生成，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。CKLFSF8相关研究可能较少，建议结合其所属的CKLF(chemokine-like factor)超家族扩大检索范围。
CKLFSF8 (chemokine-like factor superfamily member 8), also known as CMTM8. is a member of the chemokine-like factor (CKLF) superfamily, which shares structural similarities with both chemokines and transmembrane proteins. This protein is evolutionarily conserved and expressed in various tissues, with notable presence in immune cells, the testis, and the brain. It contains a conserved MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain, suggesting its potential role in membrane-associated processes such as vesicle trafficking, cell adhesion, or signal transduction.
CKLFSF8 is characterized by its transmembrane topology and involvement in regulating cellular functions, including cell proliferation, migration, and apoptosis. Studies indicate its interaction with the ubiquitin-proteasome system and its ability to modulate epidermal growth factor receptor (EGFR) degradation, linking it to cancer progression and immune regulation. For instance, CMTM8 acts as a tumor suppressor in certain cancers by downregulating oncogenic signaling pathways, while its aberrant expression correlates with poor prognosis in others, highlighting context-dependent roles.
Recombinant CKLFSF8 protein is typically produced using prokaryotic (e.g., E. coli) or eukaryotic (e.g., mammalian, insect cell) expression systems to enable functional studies. Its recombinant form facilitates research into ligand-receptor interactions, immune modulation, and cancer biology. Recent investigations also explore its potential as a therapeutic target or diagnostic marker, particularly in malignancies and inflammatory diseases. Despite progress, the precise molecular mechanisms and full spectrum of biological activities remain under active investigation, necessitating further structural and functional characterization.
×
